NovoCure Limited · NASDAQ:NVCR
NovoCure — Investor Presentation (October 2022)
35 slides from NovoCure's investor presentation, October 2022
Slide 1: Novocure October 2022
novecure’ Novocure October 2022 patientforward
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Tumor Treating Fields are electric fields that kill cancer cells
novocure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer \ » N TeleEL_L DS cells via a variety of mechanisms “ANA TUMOR TREATING FIELDS THERAPY TTFields spare healthy cells because they have different properties than cancer cells across a range of tumo
Slide 4: Tumor Treating Fields have multiple, distinct mechanisms of action
novecure’ Tumor Treating Fields have multiple, distinct mechanisms of action interference of cell movement and disruption of 4 = , mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead os downregulation of . to their death wT downstrea
Slide 5: Optune intended as a treatment for adult patients with GBM
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Slide 6: Founded in 2000, now...
FOUNDED IN 2000, NOW novecure’ PATIENTS TREATED TO DATE NET REVENUES IN Q3 2022 ONGOING PHASE 3/4 TRIALS WITH REGISTRATIONAL INTENT Together with our patients, we strive to extend survival in some of the PARTNERED IN CHINA patientforward® DIRECT DME OPERATIONS IN most aggressive forms of cancer U.S.
Slide 7: GBM business of today drives investment in the future
GBM business of today drives investment in the future net revenues! (USD in millions) operating expenses! (USD in millions) fit 5 2 @) $401.8 T | $400 ACTIVE PATIENTS ON THERAPY AS OF SEPT 30, 2022 $300 $300 ° /Th $200 $200 GROSS MARGIN ~ a‘ $970 CASH & SHORT-TERM $o ' so INVESTMENTS AS YTD 2018 YTD
Slide 8: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth , — , ~~ o ‘ a x / 4 = y / » t 5 3 \ ’ f \ \ ' PAB i , 7 “ARB 4 9. 0 Ry 4 —_) 80868 drive commercial advance deliver adoption clinical trials product innovation in approved in new indications to optimize indications and combinations TTFields th
Slide 9: Drive commercial adoption
novecure’ drive commercial adoption patientfo rward © 2022 Novocure GmbH 9
Slide 10: Glioblastoma: malignant brain cancer
novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 65: median age of newly diagnosed GBM patient2 14.6 to 16.7 months median overall survival® Early detection Is nearly 5-10% five-year survival rate imposs
Slide 11: Optune: proven to extend patient survival
novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) na Hiticnonsin-2o9,andomssirinonts) —_%09__ 60 NEARLY HALF Log-rank P-value <0,001 ° f ea le vein —_ 087 HR (95% Cl) 0.63 (0.53-0.76) 43% 3 ee Re < o74 e
Slide 12: Optune: greater exposure increased survival
novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<005 gw Optune + TMZ , = TMZ al 20 months 005 “on OF PATIENTS RECEIVED A SURVIVAL JM te montnsao0s BENEFIT FROM OPTUNE BECAUSE se months THEY USED IT >50% OF THE TIM
Slide 13: Driving commercial growth in GBM
driving commercial growth in GBM strengthen HCP increase patient COMMERCIAL PENETRATION recommendation demand IN NEWLY DIAGNOSED GBM IN ACTIVE MARKETS enter new geographic markets patient
Slide 14: Advance clinical trials
novecure’ advance clinical trials patientfo rward © 2022 Novocure GmbH 14
Slide 15: Expand label in approved indications; investigate new indications
expand label in approved indications holistic strategy to \ expand | T Fields clinical footprint investigate use in new indications © 2022 Novocure GmbH 15 patient
Slide 16: Multiple late-stage, randomized pivotal trials set to read out in near-term
novecure’ multiple late-stage, randomized pivotal trials set to read out in near-term | ENROLLMENT COMPLETE ENROLLMENT COMPLETE | ENGOT-ov50/ z AN war OP Innovaris METIS @ panovas Ovarian Cancer + Evaluating TTFields with * Evaluating TTFields with * Evaluating TTFields after + Evaluating TTFields w
Slide 17: Late-stage pipeline offers substantial, near-term market expansion opportunity
novecure’ late-stage pipeline offers substantial, near-term market expansion opportunity GLIOBLASTOMA LATE-STAGE PIPELINE 14x CURRENT MARKET OPPORUNITY PANOVA-3 Pancreatic Cancer ~35% penetrated in key markets METIS Brain Metastasis ENGOT-ov50/ INNOVATE-3 ‘Ovarian Cancer @ =1,000 addressable cases d
Slide 18: Platform technology driving robust clinical pipeline
novecure’ platform technology driving robust clinical pipeline ¢ ‘\ 1 ’ 4 \ 1 \ t v ? i 4 ---" Swany ‘ \ AY 1 H n a i’ mY ey my 4 \ iy 1 ii y pA 1 ‘ 1 4 1 ot i ae 1 Y bo patientforward PHASE 2 PHASE 3/4 APPROVED. a EF-07 primary newly diagnosed EF-14 brain glioblastoma TRIDENT cancer EF-41/KEYNOTE D
Slide 19: Deliver product innovation
novecure’ deliver product Innovation patientfo rward © 2022 Novocure GmbH 19
Slide 20: Product roadmap to prioritize efficacy and ease of use
oc product roadmap to prioritize efficacy and ease of use field generator arrays software applications next gen device flex arrays MAXPOINT™ in development limited market release upcoming planning software in development patient © 2022 Novocure GmbH 20
Slide 21: Greater dose delivered can lead to increased efficacy
greater dose delivered can lead to increased efficacy a TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY cm THERAPY TO TUMOR OF TISSUE — patient © 2022 Novocure GmbH 21 Ballo MT, et al. Correlationof Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnos
Slide 22: Flex arrays increase coverage and dose
flex arrays Increase Coverage and dose I _no_background 10 V/cm 10cm P CURRENT ARRAYS AP channel, 1,588 mAmps FLEX ARRAYS AP channel, 1,988 mAmps patient © 2022 Novocure GmbH 22 Data on file. Simulation of electric field distribution in healthy brain model
Slide 23: Flex arrays designed for more efficient delivery
novecure’ flex arrays designed for more efficient delivery ARRAY PERFORMANCE Average Current (2-Channels) 2,250 FLEX ARRAY 2,000 -e—_a—reSeease a uF 1750 CURRENT ARRAY of 1,500 1.250 SP SPP PP PP PPP PF PSP 8 LPP. P PPP PPP PPP PPP PPP PL SP LSB PPP PS Time Lapsed (Hours) ory PAP AV APS AVERAGE AVER
Slide 24: Catalyst-rich through 2024
novecure’ catalyst-rich through 2024 2021 2022 2023 2024 2024 ANTICIPATED PIVOTAL DATA LUNAR phase 3 INNOVATE-3 phase 3 LUNAR METIS IN 4 NEW INDICATIONS interim analysis interim analysis phase 3 data phase 3 data LUNAR phase 3 EF-31 gastric METIS phase 3 PANOVA-3 enrollment complete phase 2 data enr
Slide 25: Together with our patients, we strive to extend survival
together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward
Slide 26: Appendix
novocure’ appendix patientforward*
Slide 27: Ongoing LUNAR trial in non-small cell lung cancer
novecure’ ongoing LUNAR trial in non-small cell lung cancer LUNAR PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN? & ae mee CT q6wuntil dni [sels survival progression on screening 8 inhibitor/docetaxel progres follow-up visits (cliom-up or after platinum- fim baseline —— based therapy evaluatio
Slide 28: Ongoing INNOVATE-3 trial in ovarian cancer
novecure’ ongoing INNOVATE-S3 trial in ovarian cancer INNOVATE-3 PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! & TTFields + weekly [i CT/MRI scan q8w _ survival gernaore, s 7 paclitaxel until progressi follow-up a ae aS s weekly paclitaxel CT/MRI scan q8w [i survival S YP until progression f
Slide 29: Ongoing METIS trial in brain metastases
novecure’ ongoing METIS trial in brain metastases METIS PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 Ee. Tumor Treating [i MRI q2m until ro 4 radiosurger Fields rogression screening and ji 8 a sey) pres baseline evaluation € 8 a _ MRI a2 til a] NY stereotactic a F An q2m unti g radiosurge
Slide 30: Ongoing PANOVA-3 trial in pancreatic cancer
novocure ongoing PANOVA-S trial in pancreatic C PANOVA-3 PHASE 3 PIV , OPEN-LABEL, RANDOMIZED TRIAL DESIGN* 5 el 7 CT g8w until post-PD survival screening and ic gemcitabine progression follow up visit follow-up q4w baseline fe evaluation 8 nab-paclitaxel + CT g8w until post-PD survival S gemcitabin
Slide 31: Ongoing TRIDENT trial in newly diagnosed GBM
novecure’ ongoing TRIDENT trial in newly diagnosed GBM TRIDENT PHASE 4 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! TTFields + RT TTFields + MRI q8w until + TMZ maintenance TMZ progression survival follow-up screening and baseline evaluation TTFields + MRI q8w until survival Ba spb, maintenance TMZ
Slide 32: Ongoing KEYNOTE B36 trial in non-small cell lung cancer
novecure’ ongoing KEYNOTE B36 trial in non-small cell lung cancer KEYNOTE B36 PHASE 2 PILOT TRIAL DESIGN* screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival baseline evaluation JJ + pembrolizumab progression or 24 mo follow-up follow-up @ KEYNOTE B36 Lung Cancer STUDY D
Slide 33: KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study
novecure’ KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study N=26 patients Median PFS. N=26 patients Median OS oa 2-THE-TOP | 12.1 mos. 2 2-THE-TOP | 25.2 mos. = 9 EF-14 matched-control 7.9 mos. 2 Ll EF-14 matched-control 15.9 mos s = 2 (HR = 0.46; p=0.033) $ I (HR = 0.38; p=0.020) 8
Slide 34: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a
Slide 35: Warnings and precautions
novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event